


Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-80B6FCDA-EE81-48B9-97FC-461200692834\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M59510\\_03\\_01](https://doi.org/10.31003/USPNF_M59510_03_01)  
DOI Ref: l1ybq

© 2025 USPC  
Do not distribute

## Oxycodone Hydrochloride



$C_{18}H_{21}NO_4 \cdot HCl$  351.82

Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, hydrochloride, (5α)-;

4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride CAS RN®: 124-90-3; UNII: C1ENJ2TE6C.

### DEFINITION

Oxycodone Hydrochloride contains NLT 97.0% and NMT 103.0% of oxycodone hydrochloride ( $C_{18}H_{21}NO_4 \cdot HCl$ ), calculated on the anhydrous, solvent-free basis.

### IDENTIFICATION

**Change to read:**

- A. **SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197A or 197K▲ (CN 1-May-2020)

**Sample:** Dissolve 250 mg of Oxycodone Hydrochloride in 25 mL of water. Render 25 mL of the resulting solution with 6 N ammonium hydroxide. Allow the mixture to stand until a precipitate is formed. Filter, wash the precipitate with 50 mL of cold water, and dry at 105° for 2 h.

**Acceptance criteria:** Meets the requirements

- B. The retention time of the oxycodone peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Mobile phase:** 0.005 M sodium 1-hexanesulfonate, methanol, triethylamine, and phosphoric acid (900:100:2:5). Adjust with 50% sodium hydroxide solution to a pH of  $2.5 \pm 0.1$  and filter.

**System suitability solution:** 13 µg/mL of USP Codeine Phosphate RS and 9 µg/mL of USP Oxycodone RS in *Mobile phase*

**Standard solution:** 0.9 mg/mL of USP Oxycodone RS in *Mobile phase*

**Sample solution:** 1 mg/mL of Oxycodone Hydrochloride in *Mobile phase*. [NOTE—Pass a portion of this solution through a filter of 0.5-µm or finer pore size, and use the filtrate as the *Sample solution*.]

#### Chromatographic system

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 206 nm

**Column:** 3.9-mm × 15-cm; 4-µm packing L7

**Column temperature:** 50°

**Flow rate:** 1.5 mL/min

**Injection volume:** 10 µL

**Run time:** NLT 2 times the retention time of oxycodone

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for codeine and oxycodone are about 0.8 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 3.0 between codeine and oxycodone, *System suitability solution*

**Tailing factor:** 0.75–1.25, *Standard solution***Relative standard deviation:** NMT 1.10%, *Standard solution***Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of oxycodone hydrochloride ( $C_{18}H_{21}NO_4 \cdot HCl$ ) in the portion of Oxycodone Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

 $r_U$  = peak response from the *Sample solution* $r_S$  = peak response from the *Standard solution* $C_S$  = concentration of [USP Oxycodone RS](#) in the *Standard solution* (mg/mL) $C_U$  = concentration of Oxycodone Hydrochloride in the *Sample solution* (mg/mL) $M_{r1}$  = molecular weight of oxycodone hydrochloride, 351.82 $M_{r2}$  = molecular weight of oxycodone base, 315.37**Acceptance criteria:** 97.0%–103.0% on the anhydrous, solvent-free basis**IMPURITIES**

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.05%

[NOTE—Use of sulfuric acid is omitted.]

[NOTE—On the basis of the synthetic route, perform either *Procedure 1* or *Procedure 2*. *Procedure 1* is recommended if 8 $\beta$ -hydroxyoxycodone (7,8-dihydro-8 $\beta$ -14-dihydroxycodeinone) is a potential impurity.]

- **ORGANIC IMPURITIES, PROCEDURE 1**

**Mobile phase, System suitability solution, Standard solution, Sample solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.**Analysis****Sample:** *Sample solution*

Calculate the percentage of each impurity in the portion of Oxycodone Hydrochloride taken:

$$\text{Result} = (r_U/r_T) \times 100$$

 $r_U$  = peak response of each impurity from the *Sample solution* $r_T$  = sum of the responses of all the peaks from the *Sample solution***Acceptance criteria:** See [Table 1](#).**Table 1**

| Name   | Relative Retention Time | Acceptance Criteria, NMT (%) |
|--|-------------------------|------------------------------|
| Oxymorphone  | 0.31                    | 0.15                         |
| Noroxymorphone <sup>a</sup>  | 0.33                    | 0.15                         |
| 10-Hydroxyoxycodone <sup>b</sup>   | 0.53                    | 0.15                         |
| 6- $\alpha$ Oxycodol <sup>c</sup>  | 0.67                    | 0.25                         |
| 8 $\beta$ -Hydroxyoxycodone<br>(7,8-dihydro-8 $\beta$ -14-dihydroxycodeinone) <sup>d</sup> | 0.71                    | 0.15                         |

| Name                            | Relative Retention Time | Acceptance Criteria, NMT (%) |
|---------------------------------|-------------------------|------------------------------|
| Oxycodone                       | 1.00                    | —                            |
| Hydrocodone                     | 1.19                    | 0.15                         |
| Individual unspecified impurity | —                       | 0.10                         |
| Total impurities                | —                       | 2.0                          |

<sup>a</sup> 4,5 $\alpha$ -Epoxy-3,14-dihydroxymorphinan-6-one.

<sup>b</sup> 4,5 $\alpha$ -Epoxy-10 $\alpha$ ,14-dihydroxy-3-methoxy-17-methylmorphinan-6-one.

<sup>c</sup> 4,5 $\alpha$ -Epoxy-3-methoxy-17-methylmorphinan-6 $\alpha$ ,14-diol.

<sup>d</sup> 4,5 $\alpha$ -Epoxy-8 $\beta$ ,14-dihydroxy-3-methoxy-17-methylmorphinan-6-one.

• **ORGANIC IMPURITIES, PROCEDURE 2**

**Buffer:** Mix 4.0 mL of [heptafluorobutyric acid](#) with 2000 mL of [water](#) and adjust with [ammonium hydroxide](#) to a pH of 2.3 ± 0.1.

**Solution A:** [Methanol](#) and **Buffer** (23:77)

**Solution B:** [Methanol](#), [tetrahydrofuran](#), and **Buffer** (20:3:77)

**Mobile phase:** See [Table 2](#).

**Table 2**

| Time (min) | Solution A (%) | Solution B (%) |
|------------|----------------|----------------|
| 0          | 100            | 0              |
| 2          | 100            | 0              |
| 30         | 0              | 100            |
| 55         | 0              | 100            |
| 55.1       | 100            | 0              |
| 65         | 100            | 0              |

**Diluent:** [Trifluoroacetic acid](#) and [water](#) (3:1000)

**System suitability solution:** 0.0067 mg/mL each of [USP Hydrocodone RS](#) and [USP Oxycodone Related Compound A RS](#), and 3.0 mg/mL of [USP Oxycodone Hydrochloride RS](#) in **Diluent**

**Standard solution:** 0.0067 mg/mL of [USP Hydrocodone RS](#) in **Diluent**

**Sample solution:** 3.0 mg/mL of Oxycodone Hydrochloride in **Diluent**

**Chromatographic system**

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 280 nm

**Column:** 4.6-mm × 25-cm; 3- $\mu$ m packing L1

**Column temperature:** 38°

**Flow rate:** 0.8 mL/min

**Injection volume:** 50  $\mu$ L

**System suitability**

**Samples:** *System suitability solution and Standard solution*

**Suitability requirements**

**Resolution:** NLT 2.0 between oxycodone and hydrocodone; NLT 1.0 between hydrocodone and oxycodone related compound A, *System suitability solution*

Relative standard deviation: NMT 5.0%, Standard solution

**Analysis****Samples:** Standard solution and Sample solution

Calculate the percentage of each impurity in the portion of Oxycodone Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r_1}/M_{r_2}) \times (1/F) \times 100$$

 $r_U$  = peak response of each impurity from the Sample solution $r_S$  = peak response of hydrocodone from the Standard solution $C_S$  = concentration of [USP Hydrocodone RS](#) in the Standard solution (mg/mL) $C_U$  = concentration of Oxycodone Hydrochloride in the Sample solution (mg/mL) $M_{r_1}$  = molecular weight of hydrocodone hydrochloride, 335.83 $M_{r_2}$  = molecular weight of hydrocodone, 299.36 $F$  = relative response factor (see [Table 3](#))**Acceptance criteria:** See [Table 3](#). Disregard any peaks below 0.03%.**Table 3**

| Name  | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|---|-------------------------|--------------------------|------------------------------|
| Oxymorphone hydrochloride   | 0.54                    | 0.93                     | 0.15                         |
| 1-Hydroxyoxycodone hydrochloride <sup>a</sup>   | 0.69                    | 1.00                     | 0.15                         |
| 6-Oxycodol hydrochloride <sup>b</sup>   | 0.79                    | 1.16                     | 0.25                         |
| Oxycodone hydrochloride   | 1.00                    | —                        | —                            |
| Hydrocodone hydrochloride   | 1.14                    | 1.00                     | 0.50                         |
| 14-Hydroxycodeinone hydrochloride (oxycodone related compound A hydrochloride) <sup>c</sup> | 1.18                    | 0.99                     | 0.25                         |
| Noroxycodone hydrochloride <sup>d</sup>   | 1.26                    | 0.94                     | 0.50                         |
| Individual unspecified impurity   | —                       | —                        | 0.10                         |
| Total impurities  | —                       | —                        | 1.5                          |

<sup>a</sup> 4,5 $\alpha$ -Epoxy-1,14-dihydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride.<sup>b</sup> 4,5 $\alpha$ -Epoxy-3-methoxy-17-methylmorphinan-6,14-diol hydrochloride.<sup>c</sup> 4,5 $\alpha$ -Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-7-ene-6-one hydrochloride (oxycodone related compound A hydrochloride salt).<sup>d</sup> 4,5 $\alpha$ -Epoxy-14-hydroxy-3-methoxymorphinan-6-one hydrochloride.**SPECIFIC TESTS**• **CONTENT OF CHLORIDE**

**Sample solution:** 6 mg/mL of Oxycodone Hydrochloride in [methanol](#)

**Analysis:** To 50 mL of the *Sample solution*, add 5 mL of [glacial acetic acid](#) and titrate with [0.1 N silver nitrate VS](#), determining the endpoint potentiometrically. Each milliliter of 0.1 N silver nitrate is equivalent to 3.545 mg of chloride.

**Acceptance criteria:** 9.8%–10.4% on the anhydrous, solvent-free basis

- [OPTICAL ROTATION \(781S\), Procedures, Specific Rotation](#)

**Sample solution:** 25 mg/mL of Oxycodone Hydrochloride in [water](#) on the anhydrous, solvent-free basis

**Acceptance criteria:** -137° to -149°

- [WATER DETERMINATION \(921\), Method I:](#) NMT 7.0%

#### ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight containers.

• **LABELING:** The label states with which *Organic Impurities* procedure the article complies if *Organic Impurities, Procedure 1* is not used.

- [USP REFERENCE STANDARDS \(11\).](#)

[USP Codeine Phosphate RS](#)

[USP Hydrocodone RS](#)

[USP Oxycodone RS](#)

[USP Oxycodone Hydrochloride RS](#)

[USP Oxycodone Related Compound A RS](#)

Also known as 14-Hydroxycodeinone;

4,5 $\alpha$ -Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-7-ene-6-one.



**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question             | Contact   | Expert Committee          |
|----------------------------|---|---------------------------|
| OXYCODONE HYDROCHLORIDE    | <a href="#">Documentary Standards Support</a>                               | SM22020 Small Molecules 2 |
| REFERENCE STANDARD SUPPORT | RS Technical Services<br><a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a> | SM22020 Small Molecules 2 |

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 43(6)

**Current DocID:** [GUID-80B6FCDA-EE81-48B9-97FC-461200692834\\_3\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M59510\\_03\\_01](https://doi.org/10.31003/USPNF_M59510_03_01)

**DOI ref:** [l1ybq](#)